Information Provided By:
Fly News Breaks for October 23, 2015
ENTA, GILD, ABBV
Oct 23, 2015 | 08:06 EDT
Jefferies analyst Jeffrey Holford "strongly' advises investors use yesterday's selloff in shares of AbbVie as a buying opportunity. The FDA warning letter applies to a very limited population within the hepatitis C market, which means it will have a limited impact on AbbVie's HCV franchise, Holford tells investors in a research note. Competitor Gilead (GILD) has also seen excess events in the Child-Pugh B population, the analyst points out. He keeps a Buy rating on AbbVie with an $85 price target. The stock closed yesterday down $5.57 to $48.26. Its partner Enanta Pharmaceuticals (ENTA) dropped $16.35 to $23.90.
News For ABBV;GILD;ENTA From the Last 2 Days
There are no results for your query ABBV;GILD;ENTA